

Food and Drug Administration Rockville MD 20857

Re: Therma ChoiceTM Uterine Ballon Therapy System
Docket Nos.: 98E-0485 and 98E-0850

MAY | | 1999

The Honorable Q. Todd Dickinson
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, DC 20231

Dear Commissioner Dickinson:

This is in regard to the application for patent term extension for U.S. Patent Nos. 5,105,808, and 4,949,718, filed by Gynelab Products, Inc., under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the applications and have determined the regulatory review period for Therma ChoiceTM Uterine Ballon Therapy System, the medical device claimed by the patents.

The total length of the regulatory review period for Therma ChoiceTM Uterine Ballon Therapy System is 1,031 days. Of this time, 852 days occurred during the testing phase and 179 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date a clinical investigation on humans involving this device was begun: February 17, 1995.

The applicant claims that the Investigational Device Exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act for human tests to begin became effective on November 30, 1994. However, FDA records indicate that the IDE was determined substantially complete for clinical studies to have begun on February 17, 1995, which represents the IDE effective date.

2. The date the application was initially submitted with respect to the device under section 515 of the Federal Food, Drug, and Cosmetic Act: June 17, 1997.

The applicant claims June 16, 1997, as the date the Premarket Approval Application (PMA) Therma Choice™ Uterine Ballon Therapy System 5,105] (PMA P970021) was initially submitted. However, FDA records indicate that PMA P970021 was submitted on June 17, 1997.

3. The date the application was approved: December 12, 1997.

FDA has verified the applicant's claim that PMA P970021 was approved on December 12, 1997.

982-0850

LET3

This determination of the regulatory review period by FDA does not take into account the effective date of the patents, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

Thomas J. McGinnis, R.Ph.

Deputy Associate Commissioner

for Health Affairs

cc: Talivaldis Cepuritis

Olson & Hierl, Ltd.

36th Floor

20 North Wacker Drive

Chicago, IL 60606

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service Food and Drug Administration

-670 99 MAY 12 P1:49

Memorandum

Date:

MAY | | 1999

From: Brian J. Malkin, Associate Director for Patents and Hearings

Health Assessment Policy Staff (HFY-20)

Subject: Patent Term Restoration Application

for Therma Choice™ Uterine Ballon Therapy System

To: Dockets Management (HFA-305)

Attached is a letter to the Patent Term Office for the above mentioned medical device under Docket Numbers 98E-0485 and 98E-0850 stating that this particular patent is eligible for regulatory review. The Patent Numbers are 5,105,808 and 4,949,718, respectively. Please place this recent correspondence in the appropriate files.

If you have any questions, please contact me at 827-6620. Thank you for your assistance.

MAY | | 1999

DATE:

TO:

Sabrina Crisp, Regulations Policy and Management Staff, 7HF-2699 MAY 12 P1:49

From:

Brian J. Malkin, Associate Director for Patents and Hearings, HFY-20

RE:

Federal Register Notice Information for Therma ChoiceTM Uterine Ballon Therapy

System

Docket Nos. 98E-0485 and 98E-0850, FRDTS# OC99129

Attached is a FR Notice for the medical device, Therma ChoiceTM Uterine Ballon Therapy System. This document has been internally reviewed and cleared by OHA.

Please note that Therma Choice™ Uterine Ballon Therapy System is a trademark. Therefore, the superscript "TM" notation will be needed.

Please call me if you have any questions. My number is 827-6620 (Rm. 15-22).

Thank you for your assistance.